New Drug Delivery Platforms Target Fewer Injections
Adults on injectable diabetes and obesity drugs may eventually see less frequent or less invasive dosing options.
Updated on Nov. 2, 2026 in Diabetes

Daewoong Pharmaceutical presented three drug delivery platforms at PODD 2026, an international drug delivery technology conference held in Boston, United States, on October 29-30, 2026. The platforms, CURE, CLOPAM, and Thermicra, target long-acting injectables, skin-patch microneedles, and high-concentration biopharmaceutical formulations.
Why it matters
Drug delivery technology determines how often a medicine must be taken and how it is administered, which directly shapes the experience of people managing chronic conditions. Daewoong's presentation signals continued industry interest in less frequent or less invasive dosing methods for injectable drugs.
The presented results were pharmacokinetic and absorption studies conducted by the company, reported at a conference rather than in peer-reviewed publications. The source does not give sample sizes or measured effect sizes, so the strength of the findings cannot be independently assessed.
The players
Daewoong Pharmaceutical
A South Korean drugmaker whose formulation work spans long-acting injectables, microneedle patches, and biopharmaceutical formulations.
PODD 2026
An international drug delivery technology conference held in Boston that brings together researchers and developers working on how medicines are delivered to the body.
Kim Kwan-young
Head of Daewoong Pharmaceutical's Formulation Technology Center, who delivered an oral presentation at the conference.
The details
CURE is a long-acting injectable platform that uses biodegradable polymer microparticles to release drugs continuously in the body over a set period, reducing how often an injection is needed. CLOPAM is a skin-patch microneedle platform that delivers drugs through tiny needles, and the presented work examined absorption and blood-concentration changes for GLP-1 class drugs used in obesity and diabetes. Thermicra reduces the volume of biopharmaceuticals so that antibodies and antibody-drug conjugates can be given subcutaneously rather than intravenously.
Timeline
PODD 2026 was held in Boston from October 29 to 30, 2026.
Daewoong announced its participation in PODD 2026 on November 2, 2026.
Health Landscape
Long-acting injectables and microneedle patches are part of a broader push to reduce the burden of frequent injections for chronic disease treatment, including diabetes and obesity. Daewoong's platforms add to a growing set of delivery approaches that aim to move these drugs away from daily or weekly needles.
For people managing diabetes or obesity, delivery technologies like these may eventually mean fewer injections or alternatives to daily dosing, though none is described here as available for patient use. Anyone considering a change in how their medicine is given should discuss options with their physician.
The takeaway
Drug delivery innovation is focused on making treatments easier to use over the long term, not only on the medicine itself. If you rely on injectable medication, ask your doctor whether newer dosing options are relevant to your care as they become available.
Further reading
For broader context on how new delivery methods fit into care for blood sugar conditions, see Diabetes coverage.
Source note: This article includes information reported by Business Korea.


